Hormone-tracking company Eli Health raised a $12 million Series A led by BDC Capital's Thrive Venture Fund, CEO Marina Pavlovic Rivas tells Axios exclusively.
Why it matters: Eli's offering taps into a recent wave of interest in so-called longevity medicine, with dollars flowing to companies offering continuous health tracking based on biomarker tests.
